Dalbavancin Noninferior to Standard Therapy for Complicated S. Aureus Bacteremia
By Elana Gotkine HealthDay Reporter
FRIDAY, Aug. 15, 2025 -- Dalbavancin is not superior to standard therapy for adults with complicated Staphylococcus aureus bacteremia, but clinical efficacy met the criteria for noninferiority, according to a study published online Aug. 13 in the Journal of the American Medical Association.
Nicholas A. Turner, M.D., from Duke University in Durham, North Carolina, and colleagues examined the efficacy and safety of dalbavancin versus standard therapy for completion of treatment of complicated S. aureus bacteremia in a randomized clinical trial conducted from April 2021 to December 2023 at 23 U.S. medical centers. Hospitalized adults with complicated S. aureus bacteremia who achieved blood culture clearance following at least 72 hours but no more than 10 days of initial antibacterial therapy were randomly assigned to receive two doses of intravenous dalbavancin on days 1 and 8 or four to eight weeks of standard intravenous therapy (cefazolin or an antistaphylococcal penicillin if methicillin-susceptible; vancomycin or daptomycin if methicillin-resistant).
Two hundred participants were randomly assigned (100 to each group), and of these, 167 survived to day 70 and underwent an efficacy assessment. The researchers found that the probability of a more desirable day 70 outcome was 47.7 percent with dalbavancin versus standard therapy, which did not meet the criterion for superiority. Clinical efficacy was documented in 73 of 100 for dalbavancin and 72 of 100 for standard therapy, meeting the criterion for noninferiority. Serious adverse events were reported in 40 and 34 participants, respectively, who received dalbavancin and standard therapy; in both groups, treatment-related adverse events were uncommon.
"Our findings give patients and health care providers the data to support an extra choice when deciding on treatment for complicated S. aureus bacteremia," Turner said in a statement.
Several authors disclosed ties to the biopharmaceutical industry.
Abstract/Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted August 2025
Read this next
More Than 110,000 Rich's Ice Cream Bars Recalled Due to Listeria Risk
WEDNESDAY, July 23, 2025 — More than 100,000 Rich's Ice Cream Co. bars have been recalled due to possible listeria contamination. The affected ice cream bars were sold...
Association Found Between Home Mold, Hypersensitivity Pneumonitis
THURSDAY, July 17, 2025 -- Home mold, often attributed to chronic and/or recurring water intrusion, is associated with hypersensitivity pneumonitis (HP), according to a study...
Public Health Response Data Show Success of Standard Infection Control Measures for Dialysis
MONDAY, July 14, 2025 -- Adherence to standard dialysis infection prevention and control (IPC) measures enabled safe provision of dialysis to patients with Candida auris...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.